Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
M
078160
vs
K
KOSPI 200
Over the past 12 months, Medipost Co Ltd has underperformed KOSPI 200, delivering a return of -28% compared to KOSPI 200's +125% growth.
Stocks Performance
078160 vs KOSPI 200
Performance Gap
078160 vs KOSPI 200
Performance By Year
078160 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Medipost Co Ltd
Glance View
Medipost is a South Korean biotech company best known for collecting and storing umbilical cord blood and for developing cell-based medicines. Its cord blood bank service appeals to expectant parents who want to preserve newborn stem cells for possible future medical use, while its drug business focuses on regenerative treatments that are used by hospitals and doctors. The company makes money in two main ways: fees for cord blood collection and long-term storage, and sales or licensing of its cell therapy products. That mix gives it both a recurring service business and a more pharmaceutical-style business tied to approved medical products and drug development. What makes Medipost unusual is that it sits between a tissue bank and a drug maker. It handles the raw biological material, stores it under strict controls, and also turns that material into therapies for serious medical conditions. That puts it in a specialized niche of healthcare where technical expertise, regulatory approvals, and trust are all central to the business.